AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TELIX PHARMACEUTICALS LTD

9.760

-0.240-2.40%

Volume:2.00M

Turnover:19.44M

Market Cap:3.31B

PE:-327.44

High:9.860

Open:9.650

Low:9.560

Close:10.000

52wk High:29.720

52wk Low:8.260

Shares:338.72M

Float Shares:275.41M

Volume Ratio:0.63

T/O Rate:0.73%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.030

EPS(LYR):-0.030

ROE:-1.85%

ROA:1.15%

PB:5.63

PE(LYR):-327.44

Loading ...

Overview Company News Filings

Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says

MT Newswires Live

Telix Pharmaceuticals to host investor education webinar on PSMA-PET/CT imaging innovations for prostate cancer

Telix Pharmaceuticals partners with University Hospital Essen on PROMISE-PET AI PSMA-PET imaging research

Telix Pharmaceuticals Says Second Part of Prostate Cancer Study Enrolls Patients in Australia, Canada, New Zealand

MT Newswires Live

A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Strong Guidance And Gozellix Medicare Momentum

Simply Wall St.

Australian shares hit record high for second day; miners, health, tech fuel rally

Thor Medical FY 2025 loss before tax NOK 62.3 million`

How Investors Are Reacting To Telix Pharmaceuticals (ASX:TLX) 2026 Guidance, Shelf Filing And Glioma Push

Simply Wall St.

BRIEF-Telix Pharmaceuticals Ltd Files For Stock Shelf Size Not Disclosed

Telix Pharmaceuticals to Present at Oppenheimer and TD Cowen Healthcare Conferences

Telix Pharmaceuticals Ltd Files for Stock Shelf; Size Not Disclosed - SEC Filing

THOMSON REUTERS

Telix FY2025 cost of sales jumps 109% to USD 377.36 million

Telix Pharmaceuticals Ltd. Publishes 2025 Annual Report

BUZZ-Australia's Telix Pharmaceuticals soars on upbeat FY26 revenue guidance

FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment

Stock Track | Telix Pharmaceuticals Soars 5.59% Intraday on Strong Revenue Guidance

Telix Pharmaceuticals Ltd - FY 2026 Group Revenue Guidance of US$950 Million to US$970 Million.

THOMSON REUTERS

A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Its European Filing For Glioma Imaging Agent TLX101-Px

Simply Wall St.

Telix Submits European Marketing Authorization Application for TLX101-Px

Telix Submits European Marketing Authorization Application for Tlx101-Px for Brain Cancer Imaging

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TLX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":9.76,"timestamp":1772428320000,"preClose":10,"halted":0,"volume":1999028,"delay":0,"changeRate":-0.02400000000000002,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338721355,"eps":-0.02980689090112871,"marketStatus":"Not Yet Opened","change":-0.24,"latestTime":"03-02 16:12:00 AEDT","open":9.65,"high":9.86,"low":9.56,"amount":19441381,"amplitude":0.03,"askPrice":9.85,"askSize":155,"bidPrice":9.7,"bidSize":465,"shortable":3,"etf":0,"ttmEps":-0.02980689090112871,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1772492400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":10,"openAndCloseTimeList":[[1772406000000,1772427600000]],"volumeRatio":0.63383,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"1.15%","roe":"-1.85%","lyrEps":-0.029807,"volumeRatio":0.63383,"shares":338721355,"dividePrice":0,"high":9.86,"amplitude":0.03,"preClose":10,"low":9.56,"week52Low":8.26,"pbRate":"5.63","psRate":"2.91","week52High":29.72,"institutionHeld":0,"latestPrice":9.76,"committee":0.5,"eps":-0.02980689090112871,"divideRate":0,"volume":1999028,"delay":0,"ttmEps":-0.02980689090112871,"open":9.65,"prevYearClose":11.2,"prevWeekClose":10,"prevMonthClose":10,"prevQuarterClose":11.2,"fiveDayClose":9.61,"twentyDayClose":10.48,"sixtyDayClose":14.45},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771455600000,"name":null,"time":"","dateTimestamp":1771419600000,"actualEps":null},{"date":"2026-01-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1768777200000,"name":null,"time":"","dateTimestamp":1768741200000,"actualEps":null},{"date":"2025-08-21","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755734400000,"name":null,"time":"","dateTimestamp":1755698400000,"actualEps":null},{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null},{"date":"2024-08-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724284800000,"name":null,"time":"","dateTimestamp":1724248800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2616804550","title":"Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2616804550","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616804550?lang=en_us&edition=fundamental","pubTime":"2026-03-02 12:27","pubTimestamp":1772425659,"startTime":"0","endTime":"0","summary":"An organic growth in Australian healthcare services is likely due to improving availability of bulk-billing general practitioners, offset by ongoing wage pressures, Jefferies said in a Monday report.I","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FPH.AU","SHL.AU","BK7509","CU6.AU","LABU","TLX.AU","RHC.AU","HCAR","BK7113","BK7096","BK7126","COH.AU","BK4581","XAO.AU","BK7124","BK4588","XLV","XKO.AU","XBI","BK7089","SIG.AU","REG.AU","BK7067","IMM.AU","XJO.AU","IDX.AU","HLS.AU","ANN.AU","BK4585","BK7511","BK7103","MVF.AU","BK7501","CUV.AU","BK7007","NHF.AU","CSL.AU","MSB.AU","BK7508","MPL.AU","NEU.AU"],"gpt_icon":0},{"id":"2616872819","title":"Telix Pharmaceuticals to host investor education webinar on PSMA-PET/CT imaging innovations for prostate cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2616872819","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616872819?lang=en_us&edition=fundamental","pubTime":"2026-03-02 06:57","pubTimestamp":1772405851,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals to host investor education webinar on PSMA-PET/CT imaging innovations for prostate cancer               Telix Pharmaceuticals Ltd. will host an investor education webinar featuri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260301:nNDL58S1rc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","LU2095319765.USD","BK4112","LU2210150020.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","SG9999014005.SGD","BK4585","IE00BGHQF748.EUR","BK4588","SG9999014039.USD","LU0314104364.USD","TLX.AU","IE00B64PRP62.GBP","NDAQ","IE00BKPKM429.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2614485884","title":"Telix Pharmaceuticals partners with University Hospital Essen on PROMISE-PET AI PSMA-PET imaging research","url":"https://stock-news.laohu8.com/highlight/detail?id=2614485884","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614485884?lang=en_us&edition=fundamental","pubTime":"2026-02-27 20:01","pubTimestamp":1772193698,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals has entered a research collaboration with University Hospital Essen to support the PROMISE-PET registry, aiming to develop and validate AI-based prediction models for survival using standardized gallium-68 PSMA-11 PET imaging data. The partners will use Telix’s AutoML-powered AI platform to assess the prognostic value of PSMA-PET and compare model performance with established clinical risk scores to improve prostate cancer risk stratification and patient management.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL724fdF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2614886689","title":"Telix Pharmaceuticals Says Second Part of Prostate Cancer Study Enrolls Patients in Australia, Canada, New Zealand","url":"https://stock-news.laohu8.com/highlight/detail?id=2614886689","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614886689?lang=en_us&edition=fundamental","pubTime":"2026-02-27 14:19","pubTimestamp":1772173141,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) said part two of its ProstACT global study evaluating its radiopharmaceutical candidate, TLX591, for the potential treatment of patients with metastatic castration resi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","TLX","XAO.AU","XKO.AU","T10G.NZ","BK7067","NZ20C.NZ","XJO.AU","NZ50G.NZ","BK4139"],"gpt_icon":0},{"id":"2614000968","title":"A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Strong Guidance And Gozellix Medicare Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2614000968","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614000968?lang=en_us&edition=fundamental","pubTime":"2026-02-27 11:37","pubTimestamp":1772163447,"startTime":"0","endTime":"0","summary":"Why Telix’s latest guidance is attracting fresh attention\nTelix Pharmaceuticals (ASX:TLX) is back on many investors’ radar after the company issued 2026 revenue guidance of US$950 million to US$970 million and highlighted strong 2025 results supported by Gozellix uptake and Medicare reimbursement.\nSee our latest analysis for Telix Pharmaceuticals.\nThat guidance and the recent Gozellix and TLX101 Px updates have arrived after a volatile spell, with a 1 day share price return of 10.87% and a 1...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-asxtlx-valuation-after-stron","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-asxtlx-valuation-after-stron","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX","BK4139","BK7067","TLX.AU"],"gpt_icon":0},{"id":"2614109998","title":"Australian shares hit record high for second day; miners, health, tech fuel rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2614109998","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614109998?lang=en_us&edition=fundamental","pubTime":"2026-02-26 14:24","pubTimestamp":1772087046,"startTime":"0","endTime":"0","summary":"Australian shares hit record high for second day; miners, health, tech fuel rallyAXJO crosses the 9,200 mark for the first timeMiners hit record highQantas shares slump as much as 10.1%Updates to closeBy Shruti  Agarwal","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL6N3ZM09T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0823421416.USD","LU0061474705.USD","LU1712237335.SGD","LU0215105999.USD","IE00BJTD4V19.USD","LU2462157665.USD","IE00B3S45H60.SGD","LU0276348264.USD","LU1923623000.USD","LU2087621335.USD","LU2430703251.USD","IE00BQXX3F31.USD","LU0006306889.USD","LU2063271972.USD","LU1323610961.USD","BHP.AU","LU2213496289.HKD","LU0820562030.AUD","IE0004086264.USD","LU1623119135.USD","LU0308772762.SGD","SG9999001424.SGD","BK4605","IE000KEQY171.SGD","SG9999000418.SGD","LU0057025933.USD","LU2361044949.HKD","LU0957808578.USD","SG9999014898.SGD","ANV","LU2092627202.USD","LU1923622614.USD","IE00BWXC8680.SGD","LU1366192091.USD","LU0868494708.USD","IE00B775H168.HKD","LU0683600562.USD","SG9999015945.SGD","LU0310800379.SGD","LU2125909593.SGD","LU0106261372.USD","LU1718418525.SGD","LU0417517546.SGD","LU0323591593.USD","IE00BD6J9T35.USD","LU0965509283.SGD","NVII","NVIW.SI","LU2463028550.USD","LU0353189763.USD","IE00B775SV38.USD","RIO.AU","LU0079474960.USD","LU2065169927.USD","LU2097344431.USD","LU2322448791.USD","LU1629891620.HKD","LU2168564149.EUR","LU1551013425.SGD","LU1023059493.AUD","LU2168564222.USD","LU0274383776.USD","LU2360032135.SGD","LU1868837300.USD","LU1153585028.USD","LU0203201768.USD","IE00B4JS1V06.HKD","LU0158827948.USD","LU0965509101.SGD","LU1642822529.SGD","LU2430703178.SGD","LU1116320901.HKD","BK7511","LU0572940350.SGD","LU1037948897.HKD","LU1496350171.SGD","LU0011963245.USD","LU2065171311.SGD","LU0266013472.USD","SG9999014575.USD","LU2592432038.USD","LU2458330243.SGD","NVDX","LU0256863811.USD","LU0965509010.AUD","LU2471134523.USD","LU2089283258.USD","LU1064131342.USD","LU0238689110.USD","IE00BJTD4N35.SGD","LU0612318971.USD","BK7507","LU2505996681.GBP","LU0985320562.USD","LU1145028129.USD","LU1078025761.USD","LU0048584097.USD","SG9999015952.SGD","SGXZ81514606.USD","LU1868836757.USD","NVDQ","LU0942090050.USD","LU2750360997.AUD","LU2420271590.USD","BK4549","LU1935042488.USD","IE00BZ199S13.USD","LU1983260115.SGD","SG9999014567.USD","IE000W1ABFV2.USD","LU2087625088.SGD","LU0348723411.USD","LU2271345857.HKD","LU0724617625.USD","LU1935042215.USD","IE0001KFT4U8.USD","LU0170899867.USD","LU1852331112.SGD","LU1868837136.USD","BK4529","LU2089985449.USD","SG9999015978.USD","SG9999014906.USD","LU1302929846.USD","LU2756315318.SGD","LU2237957811.SGD","LU0096362180.USD","LU0689626769.HKD","LU0320765059.SGD","LU0175139822.USD","LU0456854461.SGD","LU2294711713.HKD","LU0075056555.USD","LU2065170008.USD","LU1633808545.USD","LU2471134952.CNY","LU0211328371.USD","SGXZ99366536.SGD","LU1803068979.SGD","SG9999002521.SGD","IE00BQXX3D17.EUR","LU0689472784.USD","LU1934455194.USD","LU1778281490.HKD","BK4608","LU0072462426.USD","LU0943347566.SGD","LU2361044865.SGD","LU0868494617.USD","IE00BK4W5L77.USD","LU0097036916.USD","LU0898667661.SGD","IE00BJJMRY28.SGD","LU0820561909.HKD","LU0964807845.USD","IE00BFSS7M15.SGD","LU0708995401.HKD","LU1721428933.USD","BK4587","SG9999001143.SGD","IE00B1BXHZ80.USD","IE00BN29S564.USD","LU0264606111.USD","DIPS","LU2083900584.USD","LU0654597011.USD","LU0210533765.USD","BK4614","LU2272731782.SGD","IE0003U64NQ7.SGD","IE00BJLML261.HKD","LU2244417387.USD","LU0444973449.USD","LU0494093205.USD","LU0069063385.USD","LU0511384066.AUD","LU2125154935.USD","LU0572939691.SGD","LU0823421333.USD","IE00BDRTCR15.USD","LU0171293334.USD","LU0889565833.HKD","BK4550","LU0345777147.USD","HK0000320223.HKD","LU1989764664.SGD","BK4612","LU1691799644.USD","LU2236285917.USD","LU1366333091.USD","LU2023250504.SGD","LU2403377893.USD","LU0823434583.USD","LU0265550359.USD","LU2491050154.USD","LU0345770993.USD","LU0310799852.SGD","LU2168564495.EUR","LU2458330169.SGD","NVD","LU0823434740.USD","IE00B3SWFQ91.USD","IE00BDCRKT87.USD","LU2756315664.SGD","LU0077335932.USD","LU2487616109.SGD","LU1046248800.SGD","IE00BHPRN162.USD","LU0029864427.USD","LU1839511570.USD","LU2125909247.SGD","LU2602419157.SGD","LU1674673691.USD","SG9999018865.SGD","LU0476273544.USD","LU1934455277.USD","LU1429558221.USD","LU1804176565.USD","SG9999017495.SGD","LU0234570918.USD","IE0009G5SDU7.USD","LU1699723380.USD","SG9999004303.SGD","BK4554","LU0345769128.USD","LU1861215975.USD","LU0289739343.SGD","BK7067","LU1261432733.SGD","LU2461242641.AUD","LU1435385759.SGD","IE000YTNTUN2.SGD","LU0354030438.USD","LU1066051498.USD","LU2361045086.USD","LU1935043023.USD","LU1084165304.USD","LU1989772923.USD","IE0034235071.USD","BK5111","LU0265550946.USD","LU0957791311.USD","LU2746668974.SGD","LU1066051811.HKD","IE00BQXX3C00.GBP","IE00BMPRXQ63.HKD","LU0256863902.USD","LU1935042991.SGD","LU2054465674.USD","SGXZ23171101.USD","LU0965508806.USD","LU0971552830.HKD","IE0004445015.USD","LU1130305938.SGD","LU2125909759.SGD","LU0882574139.USD","IE00BMPRXR70.SGD","BK4585","LU1868836591.USD","3NVD.UK","LU1989772840.SGD","GB00BDT5M118.USD","2NVD.UK","LU2111349929.HKD","LU2065171402.SGD","LU2089284900.SGD","LU2191332357.HKD","LU0971552673.USD","LU2471134796.USD","BK4579","LU1267930730.SGD","SG9999002224.SGD","IE00B4YYXB79.USD","BK4588","LU1951198990.SGD","LU0820561818.USD","LU1791710400.SGD","HK0000914686.HKD","LU0266512127.USD","LU0345777659.USD","BK7030","IE00BQJZX424.USD","BK4567","LU2168564065.EUR","BK4598","LU1242518931.SGD","LU0786609619.USD","LU2417539215.USD","SG9999014559.SGD","LU1309081286.SGD","IE0004091025.USD","LU1430597077.USD","LU1035775433.USD","LU2092937148.SGD","BK4551","SG9999015341.SGD","NVDU","NVDD","LU1119994496.HKD","NVDG","LU2249611893.SGD","LU2023250330.USD","LU1267930573.SGD","LU1116320737.USD","LU0056508442.USD","TLX.AU","IE00B3M56506.USD","IE0034235295.USD","LU1280957306.USD","LU0642271901.SGD","LU1720051108.HKD","LU0345780950.USD","LU0823414478.USD","LU2108987350.USD","LU2413666699.HKD","LU0187121727.USD","LU1861127337.USD","LU0788109121.HKD","LU1989764748.USD","LU1935043536.SGD","LU2452424414.USD","LU0011850046.USD","LU1037948541.HKD","IE00B1XK9C88.USD","BK4533","LU0472753341.HKD","LU2357125470.USD","LU0203202063.USD","LU1316542783.SGD","LU0107464264.USD","LU1951200564.SGD","LU0081259029.USD","LU1127390331.HKD","BK7113","LU0345781412.USD","NVDY","LU2242649171.HKD","SG9999015358.SGD","LU1571399168.USD","IE00BMPRXN33.USD","LU0342679015.USD","LU2250418816.HKD","LU0831103253.SGD","LU0161305163.EUR","LU2860962120.EUR","LU0347712357.USD","LU0330918003.SGD","LU0528227936.USD","LU1914381329.SGD","LU0096364046.USD","LU2491049909.HKD","LU2237957902.USD","LU1720051017.SGD","LU2473716301.USD","LU1861220033.SGD","LU0124676726.USD","LU0157215616.USD","LU1791710582.SGD","BK4534","LU2750360641.GBP","SG9999002232.USD","LU2265009873.SGD","LU0210536198.USD","NVDW","IE00B5949003.HKD","LU2381873111.SGD","LU2106854487.HKD","SG9999014542.SGD","IE00BYXW3230.USD","LU0345769631.USD","IE00BKPKM429.USD","BK4141","LU2505996509.AUD","SG9999014880.SGD","LU1988902786.USD","HK0000306701.USD","LU0053666078.USD","LU2543165471.USD","LU0109391861.USD","LU2357305700.SGD","LU1242518857.USD","LU0210528500.USD","LU0353189680.USD","LU2237438978.USD","LU2506951792.HKD","LU0289960550.SGD","LU0719512351.SGD","LU1066053197.SGD","LU0612318385.USD","BK4548","IE00B19Z8X17.USD","LU0094547139.USD","LU2552382132.HKD","NVDL","SGXZ51526630.SGD","IE00BJJMRX11.SGD","LU2471134879.HKD","IE00B7KXQ091.USD","SGXZ31699556.SGD","LU1066051225.USD","LU1992135472.HKD","LU0823414551.USD","LU1548497426.USD","LU0390134368.USD","LU1244550577.SGD","LU1992135399.USD","LU2896262040.SGD","LU0345770308.USD","LU2552382215.SGD","LU2746668461.USD","LU2077746001.SGD","LU2272731865.HKD","LU2023251221.USD","LU0267386448.USD","LU2125909916.SGD","SG9999018857.SGD","LU1815333072.USD","IE00B19Z8W00.USD","LU1244550221.USD","LU1814569148.SGD","LU2097344357.USD","LU0289961442.SGD","LU0505663152.USD","LU2413666426.HKD","LU2290526834.HKD","LU1917777945.USD","LU0061474960.USD","LU0979878070.USD","LU1934455863.HKD","LU0787776722.HKD","BK4543","LU0316494557.USD","LU2463526074.USD","SNVD.UK","IE00BZ1G4Q59.USD","LU0861579265.USD","LU2247934214.USD","IE0034235188.USD","BK4592","HK0000914660.USD","LU0251132253.USD","LU2242650005.HKD","LU0070217475.USD","LU2360107168.USD","IE00BKVL7J92.USD","LU0080751232.USD","IE00BFSS8Q28.SGD","LU0640476718.USD","LU1974910355.USD","LU2211815571.USD","LU0198837287.USD","LU0557290698.USD","HK0000320264.USD","LU0266512473.USD","BK4527","NVD3.UK","LU0444971666.USD","LU0082616367.USD","IE00B19Z9505.USD","LU1551013342.USD","SG9999014914.USD","BK4581","LU1064927863.SGD","LU2322448957.HKD","NVDS","LU2491050071.SGD","LU2456880835.USD","LU2360106780.USD","LU0225283273.USD","SG9999015986.USD","LU0158827781.USD","LU0061475181.USD","IE0009356076.USD","LU2430703095.HKD","LU1868836914.USD","HK0000306685.HKD","NVDS.UK","BK7095","IE0005OL40V9.USD","IE0004445239.USD","LU2272731600.USD","LU0127658192.USD","LU1821325948.USD","RHC.AU","LU0708994859.HKD","LU1232071149.USD","LU2264538146.SGD","LU0466842654.USD","LU1069344957.HKD","LU0109392836.USD","IE00BK4W5M84.HKD","LU1496350502.SGD","LU0354030511.USD","LU2125154778.USD","LU1267930490.SGD","LU2931357623.SGD","LU0128525929.USD","LU0211327993.USD","BK4503","LU0345768740.USD","LU0154236417.USD","LU2286300806.USD","IE0034235303.USD","LU0672654240.SGD","LU0955669360.SGD","LU0630314457.HKD","NVD2.UK","LU1674673428.USD","LU0345768153.USD","LU2028103732.USD","LU1923622291.USD","LU2168563687.JPY","NVDB","LU1244550494.USD","LU2326559502.SGD","LU1815336760.USD","LU2552382058.USD","LU0788109477.HKD","IE00BKDWB100.SGD","IE00BWDBJ516.SGD","IE000ITXATA3.USD","LU0234572021.USD","LU2433249047.HKD"],"gpt_icon":0},{"id":"2614993390","title":"Thor Medical FY 2025 loss before tax NOK 62.3 million`","url":"https://stock-news.laohu8.com/highlight/detail?id=2614993390","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614993390?lang=en_us&edition=fundamental","pubTime":"2026-02-26 14:19","pubTimestamp":1772086793,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Thor Medical ASA published the original content used to generate this news brief on February 26, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL2lv6wT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2614098970","title":"How Investors Are Reacting To Telix Pharmaceuticals (ASX:TLX) 2026 Guidance, Shelf Filing And Glioma Push","url":"https://stock-news.laohu8.com/highlight/detail?id=2614098970","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614098970?lang=en_us&edition=fundamental","pubTime":"2026-02-26 08:48","pubTimestamp":1772066933,"startTime":"0","endTime":"0","summary":"In February 2026, Telix Pharmaceuticals reported full-year 2025 sales of US$803.79 million alongside a small net loss of US$7.13 million, issued group revenue guidance of US$950 million to US$970 million for 2026, filed a shelf registration for its American Depositary Shares, and submitted a European marketing authorization application for its glioma imaging candidate TLX101-Px.\nA key implication of these updates is that Telix is coupling higher revenue ambitions and potential...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-investors-are-reacting-to-telix-pharmaceuticals-asxtlx-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-investors-are-reacting-to-telix-pharmaceuticals-asxtlx-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK4211","BK4139","ISBC","TLX","TLX.AU"],"gpt_icon":0},{"id":"2612626123","title":"BRIEF-Telix Pharmaceuticals Ltd Files For Stock Shelf Size Not Disclosed","url":"https://stock-news.laohu8.com/highlight/detail?id=2612626123","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612626123?lang=en_us&edition=fundamental","pubTime":"2026-02-20 20:15","pubTimestamp":1771589712,"startTime":"0","endTime":"0","summary":"BRIEF-Telix Pharmaceuticals Ltd Files For Stock Shelf Size Not Disclosed Feb 20  - Telix Pharmaceuticals Ltd TLX.AX:TELIX PHARMACEUTICALS LTD FILES FOR STOCK SHELF; SIZE NOT DISCLOSED - SEC FILINGSource text: [ID:n0001628280-26-009991]Further company coverage: TLX.AX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nFWN3ZF1LE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2612587261","title":"Telix Pharmaceuticals to Present at Oppenheimer and TD Cowen Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2612587261","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612587261?lang=en_us&edition=fundamental","pubTime":"2026-02-20 20:00","pubTimestamp":1771588830,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire  on February 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL50lG3m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014013.SGD","TLX.AU","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014005.SGD","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","LU2210149790.SGD","BK7067","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","IE00BKPKM429.USD","BK4585","BK4112"],"gpt_icon":0},{"id":"2612266201","title":"Telix Pharmaceuticals Ltd Files for Stock Shelf; Size Not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2612266201","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612266201?lang=en_us&edition=fundamental","pubTime":"2026-02-20 19:10","pubTimestamp":1771585826,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nFWN3ZF1LE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2612421266","title":"Telix FY2025 cost of sales jumps 109% to USD 377.36 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2612421266","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612421266?lang=en_us&edition=fundamental","pubTime":"2026-02-20 19:05","pubTimestamp":1771585536,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 20, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL3ZV04T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2612225532","title":"Telix Pharmaceuticals Ltd. Publishes 2025 Annual Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2612225532","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612225532?lang=en_us&edition=fundamental","pubTime":"2026-02-20 11:48","pubTimestamp":1771559322,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd. has published its Annual Report 2025, covering operations and financial position for the year ended December 31, 2025. The company reported continued growth in its precision medicine business, supported by the acquisition of RLS Radiopharmacies and the U.S. launch of Gozellix following FDA approval and reimbursement. Telix highlighted progress across its pipeline, including multiple active therapeutic pivotal trials in prostate, kidney and brain cancer, as well as ongoing work to address U.S. regulatory complete response letters for its investigational imaging candidates TLX250-Px  and TLX101-Px . The report also outlined ongoing investment in manufacturing and supply chain infrastructure, including facility milestones in Belgium, Japan and Australia, and noted the introduction of the company’s first sustainability report aligned with Australian climate-related disclosure requirements. The full report can be accessed through the link below.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL1jWCvb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2612234854","title":"BUZZ-Australia's Telix Pharmaceuticals soars on upbeat FY26 revenue guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2612234854","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612234854?lang=en_us&edition=fundamental","pubTime":"2026-02-20 07:37","pubTimestamp":1771544263,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Telix Pharmaceuticals soars on upbeat FY26 revenue guidance** Shares of Telix Pharmaceuticals TLX.AX rise as much as 9.5% to A$10, on track for best session since mid-October, 2025** Stock at highest level since February 11; best performer on S&P/ASX 200 index** Co announces revenue guidance of $950 million to $970 million for FY26, higher than $803.8 million in FY25** This is despite co posting a non-material loss before tax of $5.3 million for 2025, compared to a profit of $38 million a year earlier** Stock down 12% YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nL6N3ZF191:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2612231047","title":"FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2612231047","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612231047?lang=en_us&edition=fundamental","pubTime":"2026-02-20 07:27","pubTimestamp":1771543620,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited  today announces its financial results for the year ended December31, 2025.Group performance2: Double-digit revenue growth and positive adjusted operating cash flow. Revenue of US$803.8 million, up by 56%3 and achieving upsized full year guidance4.US$157.1 million invested in research and development (R&D) product development for late-stage therapeutics and precision medicine pipeline assets5, in line with stated FY 2025 guidance.Adjusted EBITDA6 of US$39.5 million, reflective of increased operating expenditure driven by strategic acquisitions, investment in commercial infrastructure and research and development (R&D).Year-end cash balance of US$141.9 million following US$246.4 million of strategic investments (M&A) and cash generated from operating activities of US$34.5 million before the final contingent consideration payment to Advanced Nuclear Medicine Ingredients  of US$51.8 million7","market":"fut","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/fy-2025-results-strong-commercial-growth-focused-pipeline-investment-302693191.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASX","SEC.AU","BK7095","BK4139","TLX.AU","BK7104","TAT.AU","BK7116","BK4109","BK7506","TAT","BK4526","BLA.AU","CE","BK7067","ASX.AU","BK4543","TLX","BK7039","BK4585","TMS.AU","BK4141","GBM.AU","BK4588"],"gpt_icon":0},{"id":"1172505874","title":"Stock Track | Telix Pharmaceuticals Soars 5.59% Intraday on Strong Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1172505874","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172505874?lang=en_us&edition=fundamental","pubTime":"2026-02-20 07:02","pubTimestamp":1771542151,"startTime":"0","endTime":"0","summary":"TELIX PHARMACEUTICALS LTD (TLX.AU) stock soared 5.59% during intraday trading on Friday, reflecting strong investor sentiment. The surge follows the company's release of its full-year revenue results...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX.AU"],"gpt_icon":0},{"id":"2612368482","title":"Telix Pharmaceuticals Ltd -  FY 2026 Group Revenue Guidance of US$950 Million to US$970 Million.","url":"https://stock-news.laohu8.com/highlight/detail?id=2612368482","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612368482?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:53","pubTimestamp":1771538002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nFWN3ZF1CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2612470397","title":"A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Its European Filing For Glioma Imaging Agent TLX101-Px","url":"https://stock-news.laohu8.com/highlight/detail?id=2612470397","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612470397?lang=en_us&edition=fundamental","pubTime":"2026-02-19 14:25","pubTimestamp":1771482318,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) has lodged a marketing authorization application in Europe for TLX101-Px, an 18F-FET PET imaging agent for glioma. The company is targeting broader access and more consistent diagnostic quality across major markets.\nSee our latest analysis for Telix Pharmaceuticals.\nTelix’s A$8.88 share price comes after a 1-day share price return of 0.45%, but a 30-day share price return decline of 21.28% and a 1-year total shareholder return decline of 66.89%, suggesting...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-asxtlx-valuation-after-its-e","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-asxtlx-valuation-after-its-e","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX","BK7067","BK4139","TLX.AU"],"gpt_icon":0},{"id":"2612937114","title":"Telix Submits European Marketing Authorization Application for TLX101-Px","url":"https://stock-news.laohu8.com/highlight/detail?id=2612937114","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612937114?lang=en_us&edition=fundamental","pubTime":"2026-02-18 05:55","pubTimestamp":1771365348,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd. has submitted a marketing authorization application  in Europe for TLX101-Px , its glioma imaging candidate. The submission aims to expand access to advanced PET imaging for brain cancer in major European markets and follows alignment with U.S. FDA regulatory requirements. The U.S. New Drug Application  submission is planned to follow.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire  on February 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL1kD1D0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014039.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014005.SGD","TLX.AU","LU2095319765.USD","NDAQ","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK7067","LU2210150020.SGD","SG9999014021.USD","BK4112","BK4588"],"gpt_icon":0},{"id":"2612493768","title":"Telix Submits European Marketing Authorization Application for Tlx101-Px for Brain Cancer Imaging","url":"https://stock-news.laohu8.com/highlight/detail?id=2612493768","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612493768?lang=en_us&edition=fundamental","pubTime":"2026-02-18 05:55","pubTimestamp":1771365338,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA55DRVK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":1,"totalSize":149,"code":"91000000","status":"200"}]}}